NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology

What happened

NeOnc Technologies said data from its intranasal NEO100 and oral NEO212 programs will be presented in two posters at the Society for Neuro-Oncology’s annual meeting in Philadelphia, November 12–15, 2026. The NEO100 poster will report updated results from a Phase 1/2a study and compassionate use experience.

Confirmed

Global impact / market context

The presentations put information about NeOnc’s two brain-cancer drug programs before a specialist audience, but the announcement itself does not report new results. If later data support further development, that could influence research spending, clinical trial costs, and the programs’ prospects for generating future revenue.

Analyst inference

Both programs remain clinical-stage, meaning they are still being tested rather than sold as approved treatments. The NEO100 poster concerns updated results in recurrent IDH1-mutant astrocytoma, a type of brain cancer; the supplied text gives no detailed NEO212 results or financial terms.

Confirmed

What to watch

1. The full NEO100 poster may clarify the updated study and compassionate-use findings, including whether reported outcomes support further testing; the supplied announcement does not provide those results. Analyst inference
2. The NEO212 poster is scheduled for the same meeting, but the supplied article cuts off its title, so its patient group and findings remain unspecified here. Confirmed
3. Any subsequent trial plans or spending disclosures could show whether the presentations lead NeOnc to commit more resources to either program, affecting costs before potential product revenue. Analyst inference

Evidence

• globenewswire.com